Fluid therapy in the emergency department: an expert practice review

Tim Harris,¹ ² Timothy J Coats,³ Mohammed H Elwan³ ⁴

ABSTRACT
Intravenous fluid therapy is one of the most common therapeutic interventions performed in the ED and is a long-established treatment. The potential benefits of fluid therapy were initially described by Dr W B O’Shaughnessy in 1831 and first administered to an elderly woman with cholera by Dr Thomas Latta in 1832, with a marked initial clinical response. However, it was not until the end of the 19th century that medicine had gained understanding of infection risk that practice became safer and that the practice gained acceptance. The majority of fluid research has been performed on patients with critical illness, most commonly sepsis as this accounts for around two-thirds of shocked patients treated in the ED. However, there are few data to guide clinicians on fluid therapy choices in the non-critically unwell, by far our largest patient group. In this paper, we will discuss the best evidence and controversies for fluid therapy in medically ill patients.

INTRODUCTION
Intravenous fluid therapy is one of the most common therapeutic interventions performed in the ED, and is a long-established treatment. The potential benefits of fluid therapy were initially described by Dr W B O’Shaughnessy in 1831 and first administered to an elderly woman with cholera by Dr Thomas Latta in 1832, with a marked initial clinical response. However, it was not until the end of the 19th century that doctors had gained understanding of infection risk that practice became safer and the intervention gained acceptance.

The majority of research into intravenous fluid therapy has been performed on patients with critical illness, most commonly sepsis as this accounts for around two-thirds of shocked patients treated in the ED. However, there are few data to guide clinicians on fluid therapy choices in the non-critically unwell, by far our largest patient group. In this review, we will discuss the best evidence and controversies for fluid therapy in medically ill patients.

CLINICAL SETTING
Imagine an elderly patient presenting with a pneumonia, who needs admission to hospital but is not critically unwell (normal observations). What changes in her condition would prompt you to prescribe intravenous fluids? Which fluid would you choose and in what dose? Would you prescribe intravenous fluids if her physiology was normal? This simple daily ED scenario raises a number of questions and there is likely to be great variation in practice. The deceptively simple questions of what fluid should be prescribed and how much are asked of junior doctors on a daily basis.

WHICH FLUID SHOULD I PRESCRIBE?
Normal saline was described around 150 years ago, initially to store red blood cells. It is hyperosmolar to plasma (osmolality 308 mOsm/L as compared with 275–285 mOsm/L) due to errors in calculating its composition remaining uncorrected since the initial formulation. Solutions balanced both by electrolyte composition and osmolality to approximate to (human) plasma include Hartmann’s, Ringer’s and Plasma-Lyte (table 1). However, the inability to manufacture plastic that can store bicarbonate sees all solutions replace this with an alternative, most commonly lactate, so the term ‘balanced’ is relative. Colloids were developed post-World War II to offer a cheaper alternative to albumin. Manufacturers suggested that, with these fluids, less volume would be needed for a given intravascular effect, thereby reducing tissue oedema and minimising volume infused. Data from the Saline versus Albumin Fluids Evaluation (SAFE) trial, which tested the safety of albumin in 0.9% saline as compared with 0.9% saline in patients admitted to intensive care units (ICUs) and requiring fluid bolus administration, suggest that this does not translate to clinical practice with a replacement volume ratio of 1:1.4 reported.

Data suggest that emergency physicians (EPs) most commonly prescribe 0.9% saline while colleagues in critical care favour (so-called) balanced solutions, most commonly Hartmann’s Solution in the UK. Colloids are also more rarely used in the ED.

CRYSTALLOIDS VERSUS COLLOIDS
The last 20 years has seen advances in our understanding of fluid management, but most of this literature relates to critically ill patients, in particular those who have suffered severe injury or with septic shock. A Cochrane review, which was last updated in 2013, demonstrated an association between the use of colloids (as opposed to crystalloids) and increased mortality. The 2004 SAFE trial, which took place in Australia where albumin was regularly used in resuscitation in the ICU setting due to low cost, was a large multicentre randomised controlled trial (RCT) that set out to address the issue of the advantages of crystalloid or colloid for resuscitation. This RCT provided high-quality data to support the safe use of albumin (delivered in 0.9% saline) as compared with 0.9% saline in all patient groups other than those with traumatic brain injury (potential harm in brain injury may be related to...
the hypo-osmolar albumin solution contributing to cerebral oedema). The authors followed this with a similarly large RCT to compare 6% hydroxyethyl starch (delivered in 0.9% saline) with 0.9% saline. This study showed no mortality advantage for either solution but did show a significant increase in the requirement for renal replacement therapy and higher creatinine levels in the patients randomised to 6% hydroxyethyl starch. Both trials recruited a wide range of patients admitted to ICU requiring fluid resuscitation. The ‘6s’ RCT, also performed in the ICU setting but focused on sepsis, reported an increase in mortality for patients resuscitated with 6% hydroxyethyl starch as compared with Ringer’s acetate solution. These and other trials were included in a 2013 Cochrane review, which concluded that the use of starch-based resuscitation fluids was associated with an increased mortality and renal impairment while albumin offered no significant mortality difference to crystalloids. However, were insufficient data to offer conclusions on the use of other colloids. It is likely, but not certain, that this ICU-derived data can be generalised to the ED. This leads us to recommend crystalloids over colloids for initial resuscitation in ED.

**WHICH CRYSTALLOID?**

The supraphysiological level of chloride in 0.9% saline (154 mmol/L as compared with around 96–106 mmol/L in plasma) is associated with a reduced renal blood flow and a higher rate of hyperchloeraemic acidosis after large volume infusion. Observational data suggest that the incidence of renal impairment increases with the use of 0.9% saline as compared with balanced solutions in a wide range of patient groups. A before and after ED study reported an association between chloride rich (saline) compared with chloride poor (eg, lactated Ringer’s, Plasma-Lyte) solutions and acute kidney injury. However, an ICU-based RCT showed no advantage of Plasma-Lyte as compared with saline in mortality or renal function. A recent ICU RCT showed a lower rate of the composite outcome of death, renal replacement therapy and renal dysfunction in the balanced crystalloid group compared with normal saline. Another recent ED RCT found no difference in hospital-free days in either saline or balanced crystalloid groups. However, lower incidence of major adverse kidney events was demonstrated in the saline group.

Infusion of 0.9% saline is the most common cause of in-hospital hyperchloeraemic acidosis, while Plasma-Lyte, Ringer’s and Hartmann’s solutions are associated with minimal disturbance of blood pH. The crystalloid-induced changes in lactate, electrolyte, clotting profiles and pH levels are well described but there are few data to guide clinicians on the impact of these disturbances on final clinical outcomes.

**THE BOTTOM LINE**

There is a paucity of ED-based literature so we can only base our practice by extrapolating from ICU studies, and there are no large RCTs that focus on patients who do not require resuscitation. We can guess that a crystalloid will be a reasonable first-choice intravenous fluid and that the type of fluid should be directed by the electrolytes and clinical presentation. Thus, we may choose 0.9% saline for patients with intracerebral pathology taking advantage of the higher osmolality. However, we may choose a balanced solution for patient with renal impairment and a lower pH fluid (Plasma-Lyte) for patients with acidosis.

**HOW MUCH FLUID SHOULD WE PRESCRIBE?**

This is a more complex and less well-researched question. Fluid therapy is used for resuscitation, to replace losses or prevent dehydration. Fluid research has centred around patients with shock and there is little to guide clinical practice in the other groups. Shock may be defined as life-threatening generalised maldistribution of blood flow resulting in failure to deliver and/or use adequate amounts of oxygen, leading to tissue hypoxia. The key intervention in hypovolaemic shock and the early phase of septic shock is fluid therapy. Fluids are also used to optimise cardiac output in obstructive and cardiac shock. In all cases, fluids are administered to increase stroke volume and thus cardiac output aiming at correcting tissue hypoperfusion. The underlying physiological principal is that increasing venous return increases stroke volume, the Frank-Starling law of the heart. At rest, the human heart operates below its optimal contraction sarcomere length of 2.2 μm, increasing towards this with progressive increases in venous return. Beyond this, increasing fluid loading will increase end diastolic pressure but not stroke volume, so risking increased extravascular lung water and tissue oedema.

**ASSESSMENT OF VOLUME STATUS**

As assessing stroke volume has (previously) required complex invasive devices, EDs have commonly used surrogate physiological end points to guide fluid resuscitation, such as BP, pulse and urine output. However, as shock may exist with pulse and BP within the normal range, resuscitation targeted at normalising these parameters may still be inadequate. Oliguria has been criticised as both a trigger and end point for fluid resuscitation and is no longer a therapeutic goal in recent sepsis guidelines.

The inadequacy of conventional physiological parameters and observations that patients with higher levels of oxygen delivery had improved survival saw the development of goal-directed therapy (GDT). GDT bases resuscitation on maximising oxygen delivery using predefined haemodynamic goals. This includes indirect parameters such as BP; central venous pressure (CVP) and central venous oxygen saturations and flow-based parameters (stroke volume and cardiac output) in more recent trials. Early studies suggested improved outcomes in a wide range of patients, but three large trials focused on sepsis in the ED setting showed that resuscitation against the goals of CVP and central venous oxygen saturations did not result in improved mortality compared with physician-directed care based on basic physiological parameters.
Protocolised quantitative resuscitation risks creating fluid delivered in excess of cellular requirements, with some studies suggesting this approach worsens organ perfusion and function as a consequence of fluid overload. A recent study randomised 212 adults with sepsis in ED in a resource-limited setting to either an early resuscitation protocol guided by clinical and basic monitoring parameters or usual care. Significantly higher mortality was observed in the protocol group. Similarly, in a large RCT of 3141 patients, significantly higher mortality was observed in sub-Saharan children with severe febrile illness and hypoperfusion randomised to receive a fluid bolus (saline or albumin) versus no bolus. While both studies were performed in hospitals without intensive care facilities and included respectively a high proportion of HIV-positive patients and children with malaria, these results question the current practice and guidelines of fluid resuscitation, particularly in sepsis.

CVP monitoring has been shown to be unreliable in guiding fluid therapy and is no longer recommended as a resuscitation end point. Although it can be a useful diagnostic parameter in extreme values and when its trend is combined with cardiac output measurement, it is resource intensive and carries a risk of infection and mechanical complications. Therefore, it is likely a poor choice in ED.

As inferior vena cava (IVC) diameter is a surrogate for CVP, it is subject to the same limitations. Respiratory variation in IVC has been suggested as a non-invasive measure of preload. While the IVC collapsibility index (IVCCI) has initially shown promising results in mechanically ventilated patients, studies in spontaneously breathing patients suggest a limited role. There is considerable interobserver variation and an IVCCI >30%–50% identifies patients likely to improve stroke volume with additional fluid loading, patients with lower levels of collapse <30%–50% may or may not benefit from additional fluid.

Lactate is commonly used in the ED as a marker of hypoperfusion. High lactate is an independent predictor of mortality in critically ill patients. Its use has been recommended by local and international guidelines to risk stratify patients with suspected sepsis and guide treatment. While failure to clear lactate is an ominous sign, good lactate clearance may be a misleading resuscitation end point. This is because lactataemia is both a product of aerobic mechanisms and driven by physiological/pathophysiological increases in sympathetic drive (stress response) and drug effects (eg, epinephrine, salbutamol). Thus, lactate may clear as the driving stimulus is treated (pain, agitation, medication) or as a consequence of adequate resuscitation. Lactataemia with accompanying acidosis is associated with a worse prognosis as compared with lactatemia alone.

**THE FLUID CHALLENGE**

The ability to increase stroke volume and cardiac output in response to preload challenge is termed preload responsiveness and is most commonly defined as an increase of >10%–15% following a fluid challenge. A fluid challenge is different from fluid loading, where fluids are administered without real-time monitoring. Fluid challenge, on the other hand, is a test for preload responsiveness and can be used as a controlled method for resuscitation, where a repeated fluid challenge is guided by the haemodynamic response.

The optimal volume and rate of infusion of a fluid challenge is unknown. A volume of 500 mL is the most commonly used—larger volumes may risk overload and smaller volumes may not represent a challenge. Evidence suggests that infusion over less than 30 min is more effective in detecting fluid responders. The main disadvantage of fluid challenge is that a negative test (with no increase in cardiac output or stroke volume) would mean that fluids have been irreversibly administered to patient. This is particularly important in patients at risk of overload (eg, cardiac failure and renal impairment) and if repeated fluid challenges are to be given in a short time frame. In this context, passive leg raise (PLR), a reversible self-fluid challenge, may be a more suitable alternative. PLR predicts fluid responsiveness in both spontaneously breathing and mechanically ventilated patients. Stroke volume changes resulting from a PLR may occur from some seconds to minutes after the manoeuvre and are transitory, so best assessed with continuous cardiac output monitoring or by a skilled echocardiography operator.

**SHOULD WE ASSESS FLUID RESPONSIVENESS?**

Fluid responsiveness is dictated by tissue oxygen requirements and cardiac performance, not intravascular volume. Thus, patients may be hypervolaemic and fluid responsive (eg, patients with sepsis post initial fluid resuscitation) or hypovolaemic but not fluid responsive (eg, dehydration in the setting of sepsis with acute, severely impaired left ventricular function). There is a sound theoretical framework to base fluid resuscitation on identifying fluid responders. Under resuscitation risks inadequate oxygen delivery for optimal tissue perfusion while prescribing fluids to non-responders risks fluid overload. Fluid overload in the ICU population is associated with increased mortality, length of stay, time undergoing mechanical ventilation and renal impairment. Current use of physiological markers such as pulse and BP without measurement of cardiac function means that EPs will be unaware of the effect of fluid therapy on stroke volume/cardiac output and how this is altered by either unknown existing or acquired cardiac dysfunction, or improved cardiac function resulting from medical therapy. Assessing fluid responsiveness is associated with an altered volume of fluids administered in both the ED and ICU. However, a recent systematic review found no mortality benefit for assessing fluid responsiveness in the ED setting. This included only eight studies and 489 patients highlighting the paucity of research in this field. Trials to date have focused on identifying fluid responders to maximise cardiac output and stroke volume to maximise oxygen delivery with the assumption that shock-related organ dysfunction will be rapidly reversed. However, the benefit may be that of reducing the harm of unnecessary fluid resuscitation and preventing the harm of fluid overload by identifying fluid non-responders for whom an alternative resuscitation strategy is preferred. Indeed, recent studies on the ED population report the proportion of fluid responders as 31%–85%, similar to on arrival on ICU at a later stage of resuscitation. A meta-analysis of fluid bolus therapy in the ICU setting identified an increase in cardiac index of 800 mL/min/m² immediately following the fluid bolus but this fell to 300 mL/min/m² after 60 min. The figures for mean arterial pressure and pulse rate were 7–3 mm Hg and 2–1 beats per minute. Observational data on 500 diverse ED patients who received a fluid bolus also suggest that fluid therapy has a similarly limited effect on improving BP and pulse in the ED setting. This study reported an increase in BP and decrease in HR 10 min after administering a fluid bolus but these had returned to baseline by 1 hour, presumably as the fluid delivered had redistributed from the intravascular space. There was a significant increase in RR and decrease in temperature following fluid therapy.
A simple preload/cardiac output relationship (the Frank Starling law of the heart) does not describe real life changes which are also influenced by contractility, HR, vascular tone, genetics and pre-existing disease. For example, in exercise cardiac output can increase fivefold with minimal change in preload. In Guytonian physiology, cardiac output is driven by local tissue requirements, for example, to supply oxygen to skeletal muscles in response to increased demand. The response of most normal humans who give themselves a fluid load is to increase bladder volume and not stroke volume.

THE BOTTOM LINE

It is important to appreciate the limits of what intravenous fluids can do. In sepsis there may be an intravascular fluid deficit; however, this is only one element in a complex abnormality of cardiac and both macrovascular and microvascular function. Fluid infusion may help some patients, but in patients without tissue hypoxia the lack of increased tissue demand may see fluid therapy simply redistributed and excreted. In sepsis, fluid loading may increase capillary leak to extravascular tissues and is likely to be harmful, so other interventions (eg, pressor therapy) may be required to improve tissue perfusion.

To return to the case scenarios presented, for resuscitation we support the use of crystalloids over colloids, with the choice of fluid based on electrolyte disturbance and pathology being treated. A balanced solution would be the fluid of choice unless there were specific reasons to choose 0.9% saline, such as concerns around cerebral oedema or elevated intracranial pressure. Suitable triggers for resuscitation fluid are organ failure and/or evidence (clinical or biochemical) of hypoperfusion. The risks of high-volume resuscitation are increasingly evident but the question of how much fluid is yet to be adequately answered. A pragmatic approach in the initial period is to repeat 500 mL boluses where there is no evidence of harm (such as evidence pulmonary oedema) and there is evidence of clinical or biochemical benefit (increasing BP, reducing pulse, decreasing lactate, improving metabolic acidosis). Focused echo may be useful in the initial assessment to identify shock aetiology and guide therapy, especially where poor ventricular function is identified. In the absence of any requirements for resuscitation fluids, oral fluids may be the safest option, where these are available and the patient can tolerate them.

Large, ED-based clinical trials are required to clarify whether a resuscitation strategy based around fluid responsiveness improves outcomes as compared with usual care, whether fluid therapy is better titrated to tissue perfusion as opposed to cardiovascular end points and whether oral fluids may be used in place of intravenous in patients with no evidence of tissue hypoperfusion.

CONCLUSIONS

Crystalloids are the first choice for non-blood product fluid resuscitation, balanced solutions may offer a small advantage in preserving renal function as compared with 0.9% saline. Under-resuscitation and over-resuscitation are associated with harm in critically unwell patients. Stroke volume assessment to a fluid challenge is widely used to guide fluid volumes in critical care, but is not well studied in the ED population and the optimal time of delivery and infused volumes are not established. A significant proportion of patients in the ED do not respond to infused fluids, thus applying simple physiological ‘rules’ to this complex situation may lead to overinfusion and harm. We should be wary of applying evidence derived from ICU patients, as the majority of ED patients are not critically ill and so should lobby the funders of research to invest in the large clinical trials that are required to better define optimal fluid therapy in emergency care.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES


Emerg Med J: first published as 10.1136/emermed-2017-207245 on 28 May 2018. Downloaded from http://emj.bmj.com/ on 30 May 2018 by Dr R A PEARSON 4 Hun Avenue. Protected by


